Navigation Links
Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial
Date:11/5/2011

nt placebo). No imbalance in cataract adverse events was observed in postmenopausal women with osteoporosis or in women undergoing aromatase inhibitor therapy for nonmetastatic breast cancer.

Prolia may lead to hypocalcaemia. Hypocalcaemia must be corrected by adequate intake of calcium and vitamin D before initiating therapy. ONJ has been reported rarely in clinical studies in patients receiving denosumab at a dose of 60mg every 6 months for osteoporosis.

Denosumab Commercialization Collaborations

In July 2009, Amgen and GlaxoSmithKline announced a collaboration agreement to jointly commercialize Prolia for postmenopausal osteoporosis in Europe, Australia, New Zealand and Mexico once the product is approved in these countries. Amgen will commercialize Prolia's postmenopausal osteoporosis and potential oncology indications in the U.S. and Canada and for all oncology indications in Europe and in other specified markets.

In addition, GlaxoSmithKline will register and commercialize denosumab for all indications in countries where Amgen does not currently have a commercial presence, including China, India and South Korea but excluding Japan. The structure of the collaboration allows Amgen the option of an expanded role in commercialization in both Europe and certain emerging markets in the future.

Amgen and Daiichi-Sankyo Company Limited have a collaboration and license agreement for the development and commercialization of denosumab in Japan.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
2. Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment
3. Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
4. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
5. XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
6. Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
7. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
8. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
9. XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
10. Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
11. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... -- Although colonoscopy exams prevent many colon cancer deaths ... for detecting colorectal cancers 2 , the procedure is ... EndoChoice ® Inc. today unveiled research that shows ... of this procedure and greatly reduces the number of ... clinical trial results and featuring the Fuse system that ...
(Date:5/18/2013)... , May 18, 2013 The Open ... , Occupy Psychiatry , and leading ... care, announces a social media campaign showcasing video ... psychiatric model, which focuses on pathology and illness ... with the American Psychiatric Association,s (APA) rollout of ...
(Date:5/18/2013)... , May 18, 2013 Faruqi ... firm, is investigating potential securities fraud at AVEO ... (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... and its executives violated federal securities laws by ... Company,s Phase III drug trials for Tivopath (tivozanib) ...
Breaking Medicine Technology:New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
(Date:5/18/2013)... of coffee is associated with a reduced risk ... disease, Mayo Clinic research shows. The findings were ... conference in Orlando, Fla. , PSC is ... results in inflammation and subsequent fibrosis that can ... and biliary cancer. , "While rare, PSC has ...
(Date:5/18/2013)... Utah (PRWEB) May 18, 2013 ... on insurance agents’ role in Marketplaces . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... Health and Human Services (HHS) recently released a ...
(Date:5/18/2013)... The “World Healthcare IT Market: Trends & ... market drivers, restraints, and opportunities in North America, Europe, ... 89 market data tables , ... IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , ... The global healthcare IT market is expected to grow ...
(Date:5/18/2013)... 18, 2013 As metal-on-metal hip ... the country, Bernstein Liebhard LLP notes that a new ... suffer tissue damage before they experience any pain from ... Science Daily will appear in the Journal of Bone ... MRI screens of their hips. The researchers found ...
(Date:5/18/2013)... “Sleep Apnea Diagnostic & Therapeutic Devices Market [Polysomnographs, Respiratory ... Appliances, Nasal EPAP, Neurostimulation] Global End-user Analysis, Competitive Landscape ... market drivers, restraints, and opportunities in North America, Europe, ... 147 market data tables ... 318 pagesand in-depth TOC of “Sleep Apnea Diagnostic ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3
... , FRIDAY, Feb. 18 (HealthDay News) -- Patients with ... radiation treatments have a much lower long-term survival rate than ... the study of patients with squamous cell carcinoma of the ... to smoke were still alive five years after treatment, compared ...
... Scientists at the Children,s Center for Cancer and Blood ... Los Angeles today announced a breakthrough discovery in understanding ... a protein called CD19-ligand (CD19-L) located on the surface ... and destruction of leukemia cells by the immune system. ...
... 18 (HealthDay News) -- Speaking more than one language may ... that bilingual speakers outperform people who speak only one language ... irrelevant information to focus on important information. This means bilingual ... than one project at a time, said Judith Kroll, ...
... bigger role in the American health care system, argued ... conference of the American Association for the Advancement of ... health care costs depend on the policy context in ... Meltzer, Associate Professor of Medicine, in his presentation, "Policies ...
... leading lung cancer screening researchers, doctors and advocates. ... Early Lung Cancer Action Program (I-ELCAP) Screening Conferences. ... International Early Lung Cancer Action Program (I-ELCAP) and ... International Lung Cancer Consortium (ILCCO). This meeting ...
... (Feb 18, 2011) James C. Wittig, M.D., chief ... the John Theurer Cancer Center at Hackensack University Medical ... approaches to orthopedic oncology at the upcoming American Academy ... inventing some of the most-used best practices in limb-sparing ...
Cached Medicine News:Health News:Smoking During Head & Neck Cancer Therapy Tied to Poor Outcome 2Health News:Scientists bioengineer a protein to fight leukemia 2Health News:Cost-effectiveness research needs to be considered in developing new medical technology 2Health News:World's largest lung cancer screening conference to address benefits of CT scans 2Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 2Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 3Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 4Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 5Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 6Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 7
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... The AccuDrain System is a panel mounted system ... many critical needs of the heath care professional ... drainage system available with a dual action lever ... quickly attached to an IV pole. Similarly, ...
Medicine Products: